180 Life Sciences develops novel therapies for inflammation and pain focusing on innovative biotechnology.

180 Life Sciences (NASDAQ:ATNF) is a biotechnology company focused on the development of novel therapies to combat inflammation, fibrosis, and pain. Operating at the cutting edge of medical research, their projects range from preclinical to Phase 2 clinical trials across various indications. These include addressing diseases such as Dupuytren’s contracture, Frozen shoulder, and Post-surgical pain, aiming to meet significant unmet medical needs. The objectives of 180 Life Sciences revolve around advancing these pioneering treatments through rigorous testing, aligning with regulatory approvals to eventually bring transformative solutions to patients globally. With a commitment to innovative science and patient well-being, they aim to lead advancements in biotechnology and therapeutic discovery.
GET YOUR GRAFA EDGE NOW
Sign up free to follow this company
We'll switch on a 30-day Edge trial as a welcome gift